核医学治療の医療利用（2） これからの発展に向けた課題と取り組み
Saved in:
| Published in | 保健物理 Vol. 59; no. 2; pp. 73 - 82 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | Japanese |
| Published |
一般社団法人日本保健物理学会
06.06.2024
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0367-6110 1884-7560 |
| DOI | 10.5453/jhps.59.73 |
Cover
| Author | 孫田, 惠一 花岡, 宏平 右近, 直之 宮司, 典明 米山, 寛人 飯森, 隆志 前田, 貴雅 山下, 康輔 |
|---|---|
| Author_xml | – sequence: 1 fullname: 宮司, 典明 organization: （公大）福島県立医科大学保健科学部診療放射線科学科 – sequence: 1 fullname: 右近, 直之 organization: （公大）福島県立医科大学先端臨床研究センター – sequence: 1 fullname: 飯森, 隆志 organization: 千葉大学医学部附属病院放射線部 – sequence: 1 fullname: 花岡, 宏平 organization: 近畿大学高度先端総合医療センターPET 分子イメージング部 – sequence: 1 fullname: 米山, 寛人 organization: 金沢大学附属病院放射線部 – sequence: 1 fullname: 孫田, 惠一 organization: 北海道大学病院医療技術部（放射線部門） – sequence: 1 fullname: 前田, 貴雅 organization: （国研）量子科学技術研究開発機構QST病院 – sequence: 1 fullname: 山下, 康輔 organization: （公財）がん研究会有明病院画像診断センター |
| BookMark | eNo9jztLA0EUhQeJ4BrT-B8sd72zd-48CgsJPgIBG62H2UfMLjGG3TSWWkWwtElnJabQwkpI_o1sUuYvuEGxOed8pzhwdlljeDtMGdvnEJAgPMz7ozIgEyjcYh7XWviKJDSYByiVLzmHHdYqyywCAIM1k8cOli9f1dO8en9dfs5X04fv-48a61BNZqvnt_ViEq4Xj3tsu-cGZdr68ya7Oj25bJ_73YuzTvu46-ecc-cnPdD1tOBSkxGJBIUJcNIqwTQiiRhGMtHaEIpYS4URkFAodByTMRoNNtnR725ejt11akdFduOKO-uKcRYPUrt5aMnYcCMK__u47wqbO_wBjvhYGg |
| ContentType | Journal Article |
| Copyright | 2024 日本保健物理学会 |
| Copyright_xml | – notice: 2024 日本保健物理学会 |
| DOI | 10.5453/jhps.59.73 |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 1884-7560 |
| EndPage | 82 |
| ExternalDocumentID | article_jhps_59_2_59_73_article_char_ja |
| GroupedDBID | 2WC ACGFS ALMA_UNASSIGNED_HOLDINGS ARCSS JSF KQ8 OK1 RJT |
| ID | FETCH-LOGICAL-j111a-df080094168594d6073d01587d3eb56332b6d889534c8673b0547348cc5998393 |
| ISSN | 0367-6110 |
| IngestDate | Wed Sep 03 06:30:33 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 2 |
| Language | Japanese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-j111a-df080094168594d6073d01587d3eb56332b6d889534c8673b0547348cc5998393 |
| OpenAccessLink | https://www.jstage.jst.go.jp/article/jhps/59/2/59_73/_article/-char/ja |
| PageCount | 10 |
| ParticipantIDs | jstage_primary_article_jhps_59_2_59_73_article_char_ja |
| PublicationCentury | 2000 |
| PublicationDate | 2024/06/06 |
| PublicationDateYYYYMMDD | 2024-06-06 |
| PublicationDate_xml | – month: 06 year: 2024 text: 2024/06/06 day: 06 |
| PublicationDecade | 2020 |
| PublicationTitle | 保健物理 |
| PublicationTitleAlternate | 保健物理 |
| PublicationYear | 2024 |
| Publisher | 一般社団法人日本保健物理学会 |
| Publisher_xml | – name: 一般社団法人日本保健物理学会 |
| References | 26) N. MIYAJI, K. YAMASHITA, H. YONEYAMA, K. HANAOKA, N. UKON, et al.; The questionnaire survey of Japanese practice and environment for targeted radionuclide therapy in 2021, Nihon Hoshasen Gijutsu Gakkai Zasshi, 79, 262–270 (2023) (in Japanese). 30) The Japan Radiological Society, the Japanese Society of Nuclear Medicine, the Japanese Urological Association, the Japan Society of Radiological Technology, the Japanese Society for Radiation Oncology; Enyuuryouhoo shori (Ra-223) chuushaeki wo mochiiru naiyou iryohou (kakunikugaku chiryou) no tekisei shiyou manyuaru dai 2 han [The Proper Use Manual for Internal Therapy Using Radium Chloride (Ra-223) Injection, Second Edition] (2023) (in Japanese 38) National Institutes for Quantum Science and Technology; Hyōōteki aisotōpu chiryō ga kanōna, sekai hatsu no idōgata RI chiryō shisetsu o seisaku-chiryō kōka ga takai arufa-sen gan chiryō o mijikai ni [Development of the World's First Mobile Radionuclide Therapy Facility for Targeted Isotope Therapy ō Bringing High-Efficacy Alpha Particle Cancer Treatment Closer to Home] (in Japanese) Available at: https://www.qst.go.jp/site/press/20220707.html. Accessed 10 January 2024. 19) PA. JACKSON, MS. HOFMAN, RJ. HICKS, M. SCALZO and J. VIOLET; Radiation dosimetry in 177Lu-PSMA-617 therapy using a single posttreatment SPECT/CT scan: a novel methodology to generate time- and tissue-specific dose factors, J. Nucl. Med., 61, 1030–1036 (2020). 29) N. MATSUTOMO, M. FUKAMI, T. KOIKE and T. YAMAMOTO; Estimation of eye lens dose during the handling of radiopharmaceuticals and using X-ray protective goggles for dose reduction in nuclear medicine, Nihon Hoshasen Gijutsu Gakkai Zasshi, 78, 348–356 (2022) (in Japanese). 11) JC. DICKSON, IS. ARMSTRONG, PM. GABIÑA, AM. DENIS-BACELAR, AK KRIZSAN, et al.; EANM practice guideline for quantitative SPECT-CT, Eur. J. Nucl. Med. Mol. Imaging, 50 (4), 980–995 (2023). 31) L. JØDAL; Beta emitters and radiation protection, Acta. Oncol., 48, 308–313 (2009). 37) K. OKUHATA, H. MONZEN, Y. NAKAMURA, G. TAKAI, K. NAGANO, et al.; Effectiveness of shielding materials against 177Lu gamma rays and the corresponding distance relationship, Ann. Nucl. Med., 37, 629–634 (2023). 2) E. OSTUNI and MRG. TAYLOR; Commercial and business aspects of alpha radioligand therapeutics, Front Med (Lausanne), 2, 9, 1070497 (2023). 20) T. SAKASHITA, S. WATANABE, H. HANAOKA, Y. OHSHIMA, Y. IKOMA, et al.; Absorbed dose simulation of meta-211At-astato-benzylguanidine using pharmacokinetics of 131I-MIBG and a novel dose conversion method, RAP, Ann. Nucl. Med., 35, 121–131 (2021). 6) J. TRAN-GIA, AM. DENIS-BACELAR, KM. FERREIRA, AP. ROBINSON, N. CALVERT, et al.; A multicentre and multi-national evaluation of the accuracy of quantitative 177Lu SPECT/CT imaging performed within the MRTDosimetry project, EJNMMI Phys., 23, 8 (1), 55 (2021). 36) T. MURATA, K. MIWA, F. MATSUBAYASHI, K. WAGATSUMA, K. AKIMOTO, et al.; Optimal radiation shielding for beta and bremsstrahlung radiation emitted by(89)Sr and (90)Y: validation by empirical approach and Monte Carlo simulations, Ann. Nucl. Med., 28, 617–622 (2014). 7) C. URIBE, A. PETERSON, B. VAN, R. FEDRIGO, J. CARLSON, et al.; An international study of factors affecting variability of dosimetry calculations, Part 1: Design and Early Results of the SNMMI dosimetry challenge, J. Nucl. Med., 62, 36S–47S (2021). 10) N. FUJITA, Y. KOSHIBA, S. ABE and K. KATO; Investigation of post-therapeutic image-based thyroid dosimetry using quantitative SPECT/CT, iodine biokinetics and the MIRD’s voxel S values in Graves’ disease, EJNMMI Phys., 7, 6 (2020). 13) M. SANDSTRÖM, E. ILAN, A. KARLBERG, S. JOHANSSON, N. FREEDMAN, et al.; Method dependence, observer variability and kidney volumes in radiation dosimetry of (177) Lu-DOTATATE therapy in patients with neuroendocrine tumours, EJNMMI Phys., 2, 24 (2015). 34) A. RIMPLER and I. BARTH; Beta radiation exposure of medical staff and implications for extremity dose monitoring, Radiat. Prot. Dosim., 25, 335–339 (2007). 14) T. LI, ECI. AO, B. LAMBERT, B. BRANS, S.VANDENBERGHE, et al.; Quantitative imaging for targeted radionuclide therapy dosimetry-technical review, Theranostics, 7, 4551–4565 (2017). 33) The Japan Radiological Society, the Japanese Society of Nuclear Medicine, the Japanese Society of Hematology, the Japanese Society for Radiation Oncology; Yttoriumu-90 Hyoushiki Kou CD20 Koutai wo Mochiita Housha Men'ekiryouhou no Tekisei Shiyou Manyuaru Dai 3-han [The Proper Use Manual for Radioimmunotherapy Using Yttrium-90-Labeled Anti-CD20 Antibodies, 3rd Edition] (2019) (in Japanese). 35) A. RIMPLER, I. BARTH, RB. BAUM, S. SENFTLEBEN and L. GEWORSKI; Beta radiation exposure of staff during and after therapies with 90Y label led substances, Radiat. Prot. Dosim., 131, 73–79 (2008). 8) TI. GÖTZ, C. SCHMIDKONZ, EW. LANG, A. MAIER, T. KUWERT, et al.; Factors affecting accuracy of S values and determination of time-integrated activity in clinical 177Lu dosimetry, Ann. Nucl. Med., 33, 521–531 (2019). 21) N. UKON, S. ZHAO, K. WASHIYAMA, N. ORIUCHI, C. TAN, et al.; Human dosimetry of free 211At and meta-[211At] astatobenzylguanidine (211At-MABG) estimated using preclinical biodistribution from normal mice, EJNMMI Phys., 7, 58 (2020). 16) K. SJÖGREEN GLEISNER, N. CHOUIN, PM. GABINA, F. CICONE, S. GNESIN, et al.; EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands, Eur. J. Nucl. Med. Mol. Imaging, 49, 1778–1809 (2022). 18) M. LJUNGBERG, A. CELLER, MW. KONIJNENBERG, KF. ECKERMA, YK. DEWARAJA, et al.; MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative 177Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy, J. Nucl. Med., 57, 151–162 (2016). 9) Japan Thyroid Association; Basedobyo tiryou guidline 2019 [The Graves’ Disease Treatment Guidelines 2019], Nankodo Co., Ltd. Tokyo (2019) (in Japanese). 12) J. CACICEDO, A. NAVARRO-MARTIN, S. GONZALEZ-LARRAGAN, B. DE BARI, A. SALEM, et al.; Systematic review of educational interventions to improve contouring in radiotherapy, Radiother. Oncol., 144, 86–92 (2020). 1) K. HERRMANN, M. SCHWAIGER, JS. LEWIS, SB. SOLOMON, BJ. MCNEIL, et al.; Radiotheranostics: a roadmap for future development, Lancet Oncol., 21, e146–e156 (2020). 25) R. DANIELI, A. MILANO, S. GALLO, I. VERONESE, A. LASCIALFARI, et al.; Personalized dosimetry in targeted radiation therapy: a look to methods, tools and critical aspects, J. Pers. Med., 12, 205 (2022). 24) T. SATO, T. FURUTA, Y. LIU, S. NAKA, S. NAGAMORI, et al.; Individual dosimetry system for targeted alpha therapy based on PHITS coupled with microdosimetric kinetic model, EJNMMI Phys., 8, 4 (2021). 28) MO. BERNIER, N. JOURNY, D. VILLOING, MM. DOODY, BH. ALEXANDER, et al.; Cataract risk in a cohort of U. S. radiologic technologists performing nuclear medicine procedures, Radiology, 286, 592–601 (2018). 27) ICRP; ICRP Statement on tissue reactions/ early and late effects of radiation in normal tissues and organs-threshold doses for tissue reactions in a radiation protection context, ICRP Publication 118, Ann. ICRP, 41 (1/2) (2012). 32) M. CREMONESI, M. FERRARI, G. PAGANELLI, A. ROSSI, M. CHINOL, et al.; Radiation protection in radionuclide therapies with (90)Y-conjugates: risks and safety, Eur. J. Nucl. Med. Mol. Imaging, 33, 1321–1327 (2006). 5) European Society of Radiology (ESR); Summary of the European Directive 2013/59/Euratom: essentials for health professionals inradiology, Insights Imaging, 6, 411–417 (2015). 3) N. MIYAJI, N. MAEDA, N. UKON, H. YONEYAMA, K. YAMASHITA, et al.; Clinical practice for nuclear medicine therapy; Part 1 ─Developments to date and the role of radiological technology─, Jpn. J. Health Phys., 57, 172–180 (2022) (in Japanese). 4) JC. DICKSON, IS. ARMSTRONG, PM. GABIÑA, AM. DENIS-BACELAR, AK. KRIZSAN, et al.; EANM practice guideline for quantitative SPECT-CT, Eur. J. Nucl. Med. Mol. Imaging, 50 (4), 980–995 (2023). 15) WE. BOLCH, KF. ECKERMAN, G. SGOUROSA and SR. THOMAS; MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry ─standardization of nomenclature. J. Nucl. Med.. 50, 477–84 (2009). 17) KS. GLEISNER, G. BROLIN, A. SUNDLÖV, E. MJEKIQI, K. ÖSTLUND, et al.; Long-term retention of 177Lu/177mLu-DOTATATE in patients investigated by γ-spectrometry and γ-camera imaging, J. Nucl. Med., 56, 976–984 (2015). 23) LM. CARTER, TM. CRAWFORD, T. SATO, T. FURUTA, C. CHOI, et al.; PARaDIM: a PHITS-based Monte Carlo tool for internal dosimetry with tetrahedral mesh computational phantoms, J. Nucl. Med., 60, 1802–1811 (2019). 22) ET. HIPPELÄINEN, MJ. TENHUNEN, HO. MÄENPÄÄ, JJ. HEIKKONEN and AO. SOHLBERG; Dosimetry software Hermes Internal Radiation Dosimetry: from quantitative image reconstruction to voxel-level absorbed dose distribution, Nucl. Med. Commun., 38, 357–365 (2017). |
| References_xml | – reference: 14) T. LI, ECI. AO, B. LAMBERT, B. BRANS, S.VANDENBERGHE, et al.; Quantitative imaging for targeted radionuclide therapy dosimetry-technical review, Theranostics, 7, 4551–4565 (2017). – reference: 30) The Japan Radiological Society, the Japanese Society of Nuclear Medicine, the Japanese Urological Association, the Japan Society of Radiological Technology, the Japanese Society for Radiation Oncology; Enyuuryouhoo shori (Ra-223) chuushaeki wo mochiiru naiyou iryohou (kakunikugaku chiryou) no tekisei shiyou manyuaru dai 2 han [The Proper Use Manual for Internal Therapy Using Radium Chloride (Ra-223) Injection, Second Edition] (2023) (in Japanese) – reference: 28) MO. BERNIER, N. JOURNY, D. VILLOING, MM. DOODY, BH. ALEXANDER, et al.; Cataract risk in a cohort of U. S. radiologic technologists performing nuclear medicine procedures, Radiology, 286, 592–601 (2018). – reference: 35) A. RIMPLER, I. BARTH, RB. BAUM, S. SENFTLEBEN and L. GEWORSKI; Beta radiation exposure of staff during and after therapies with 90Y label led substances, Radiat. Prot. Dosim., 131, 73–79 (2008). – reference: 18) M. LJUNGBERG, A. CELLER, MW. KONIJNENBERG, KF. ECKERMA, YK. DEWARAJA, et al.; MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative 177Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy, J. Nucl. Med., 57, 151–162 (2016). – reference: 3) N. MIYAJI, N. MAEDA, N. UKON, H. YONEYAMA, K. YAMASHITA, et al.; Clinical practice for nuclear medicine therapy; Part 1 ─Developments to date and the role of radiological technology─, Jpn. J. Health Phys., 57, 172–180 (2022) (in Japanese). – reference: 20) T. SAKASHITA, S. WATANABE, H. HANAOKA, Y. OHSHIMA, Y. IKOMA, et al.; Absorbed dose simulation of meta-211At-astato-benzylguanidine using pharmacokinetics of 131I-MIBG and a novel dose conversion method, RAP, Ann. Nucl. Med., 35, 121–131 (2021). – reference: 17) KS. GLEISNER, G. BROLIN, A. SUNDLÖV, E. MJEKIQI, K. ÖSTLUND, et al.; Long-term retention of 177Lu/177mLu-DOTATATE in patients investigated by γ-spectrometry and γ-camera imaging, J. Nucl. Med., 56, 976–984 (2015). – reference: 38) National Institutes for Quantum Science and Technology; Hyōōteki aisotōpu chiryō ga kanōna, sekai hatsu no idōgata RI chiryō shisetsu o seisaku-chiryō kōka ga takai arufa-sen gan chiryō o mijikai ni [Development of the World's First Mobile Radionuclide Therapy Facility for Targeted Isotope Therapy ō Bringing High-Efficacy Alpha Particle Cancer Treatment Closer to Home] (in Japanese) Available at: https://www.qst.go.jp/site/press/20220707.html. Accessed 10 January 2024. – reference: 26) N. MIYAJI, K. YAMASHITA, H. YONEYAMA, K. HANAOKA, N. UKON, et al.; The questionnaire survey of Japanese practice and environment for targeted radionuclide therapy in 2021, Nihon Hoshasen Gijutsu Gakkai Zasshi, 79, 262–270 (2023) (in Japanese). – reference: 37) K. OKUHATA, H. MONZEN, Y. NAKAMURA, G. TAKAI, K. NAGANO, et al.; Effectiveness of shielding materials against 177Lu gamma rays and the corresponding distance relationship, Ann. Nucl. Med., 37, 629–634 (2023). – reference: 7) C. URIBE, A. PETERSON, B. VAN, R. FEDRIGO, J. CARLSON, et al.; An international study of factors affecting variability of dosimetry calculations, Part 1: Design and Early Results of the SNMMI dosimetry challenge, J. Nucl. Med., 62, 36S–47S (2021). – reference: 34) A. RIMPLER and I. BARTH; Beta radiation exposure of medical staff and implications for extremity dose monitoring, Radiat. Prot. Dosim., 25, 335–339 (2007). – reference: 10) N. FUJITA, Y. KOSHIBA, S. ABE and K. KATO; Investigation of post-therapeutic image-based thyroid dosimetry using quantitative SPECT/CT, iodine biokinetics and the MIRD’s voxel S values in Graves’ disease, EJNMMI Phys., 7, 6 (2020). – reference: 21) N. UKON, S. ZHAO, K. WASHIYAMA, N. ORIUCHI, C. TAN, et al.; Human dosimetry of free 211At and meta-[211At] astatobenzylguanidine (211At-MABG) estimated using preclinical biodistribution from normal mice, EJNMMI Phys., 7, 58 (2020). – reference: 1) K. HERRMANN, M. SCHWAIGER, JS. LEWIS, SB. SOLOMON, BJ. MCNEIL, et al.; Radiotheranostics: a roadmap for future development, Lancet Oncol., 21, e146–e156 (2020). – reference: 6) J. TRAN-GIA, AM. DENIS-BACELAR, KM. FERREIRA, AP. ROBINSON, N. CALVERT, et al.; A multicentre and multi-national evaluation of the accuracy of quantitative 177Lu SPECT/CT imaging performed within the MRTDosimetry project, EJNMMI Phys., 23, 8 (1), 55 (2021). – reference: 22) ET. HIPPELÄINEN, MJ. TENHUNEN, HO. MÄENPÄÄ, JJ. HEIKKONEN and AO. SOHLBERG; Dosimetry software Hermes Internal Radiation Dosimetry: from quantitative image reconstruction to voxel-level absorbed dose distribution, Nucl. Med. Commun., 38, 357–365 (2017). – reference: 27) ICRP; ICRP Statement on tissue reactions/ early and late effects of radiation in normal tissues and organs-threshold doses for tissue reactions in a radiation protection context, ICRP Publication 118, Ann. ICRP, 41 (1/2) (2012). – reference: 4) JC. DICKSON, IS. ARMSTRONG, PM. GABIÑA, AM. DENIS-BACELAR, AK. KRIZSAN, et al.; EANM practice guideline for quantitative SPECT-CT, Eur. J. Nucl. Med. Mol. Imaging, 50 (4), 980–995 (2023). – reference: 19) PA. JACKSON, MS. HOFMAN, RJ. HICKS, M. SCALZO and J. VIOLET; Radiation dosimetry in 177Lu-PSMA-617 therapy using a single posttreatment SPECT/CT scan: a novel methodology to generate time- and tissue-specific dose factors, J. Nucl. Med., 61, 1030–1036 (2020). – reference: 32) M. CREMONESI, M. FERRARI, G. PAGANELLI, A. ROSSI, M. CHINOL, et al.; Radiation protection in radionuclide therapies with (90)Y-conjugates: risks and safety, Eur. J. Nucl. Med. Mol. Imaging, 33, 1321–1327 (2006). – reference: 24) T. SATO, T. FURUTA, Y. LIU, S. NAKA, S. NAGAMORI, et al.; Individual dosimetry system for targeted alpha therapy based on PHITS coupled with microdosimetric kinetic model, EJNMMI Phys., 8, 4 (2021). – reference: 16) K. SJÖGREEN GLEISNER, N. CHOUIN, PM. GABINA, F. CICONE, S. GNESIN, et al.; EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands, Eur. J. Nucl. Med. Mol. Imaging, 49, 1778–1809 (2022). – reference: 13) M. SANDSTRÖM, E. ILAN, A. KARLBERG, S. JOHANSSON, N. FREEDMAN, et al.; Method dependence, observer variability and kidney volumes in radiation dosimetry of (177) Lu-DOTATATE therapy in patients with neuroendocrine tumours, EJNMMI Phys., 2, 24 (2015). – reference: 12) J. CACICEDO, A. NAVARRO-MARTIN, S. GONZALEZ-LARRAGAN, B. DE BARI, A. SALEM, et al.; Systematic review of educational interventions to improve contouring in radiotherapy, Radiother. Oncol., 144, 86–92 (2020). – reference: 9) Japan Thyroid Association; Basedobyo tiryou guidline 2019 [The Graves’ Disease Treatment Guidelines 2019], Nankodo Co., Ltd. Tokyo (2019) (in Japanese). – reference: 33) The Japan Radiological Society, the Japanese Society of Nuclear Medicine, the Japanese Society of Hematology, the Japanese Society for Radiation Oncology; Yttoriumu-90 Hyoushiki Kou CD20 Koutai wo Mochiita Housha Men'ekiryouhou no Tekisei Shiyou Manyuaru Dai 3-han [The Proper Use Manual for Radioimmunotherapy Using Yttrium-90-Labeled Anti-CD20 Antibodies, 3rd Edition] (2019) (in Japanese). – reference: 2) E. OSTUNI and MRG. TAYLOR; Commercial and business aspects of alpha radioligand therapeutics, Front Med (Lausanne), 2, 9, 1070497 (2023). – reference: 15) WE. BOLCH, KF. ECKERMAN, G. SGOUROSA and SR. THOMAS; MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry ─standardization of nomenclature. J. Nucl. Med.. 50, 477–84 (2009). – reference: 25) R. DANIELI, A. MILANO, S. GALLO, I. VERONESE, A. LASCIALFARI, et al.; Personalized dosimetry in targeted radiation therapy: a look to methods, tools and critical aspects, J. Pers. Med., 12, 205 (2022). – reference: 23) LM. CARTER, TM. CRAWFORD, T. SATO, T. FURUTA, C. CHOI, et al.; PARaDIM: a PHITS-based Monte Carlo tool for internal dosimetry with tetrahedral mesh computational phantoms, J. Nucl. Med., 60, 1802–1811 (2019). – reference: 8) TI. GÖTZ, C. SCHMIDKONZ, EW. LANG, A. MAIER, T. KUWERT, et al.; Factors affecting accuracy of S values and determination of time-integrated activity in clinical 177Lu dosimetry, Ann. Nucl. Med., 33, 521–531 (2019). – reference: 5) European Society of Radiology (ESR); Summary of the European Directive 2013/59/Euratom: essentials for health professionals inradiology, Insights Imaging, 6, 411–417 (2015). – reference: 29) N. MATSUTOMO, M. FUKAMI, T. KOIKE and T. YAMAMOTO; Estimation of eye lens dose during the handling of radiopharmaceuticals and using X-ray protective goggles for dose reduction in nuclear medicine, Nihon Hoshasen Gijutsu Gakkai Zasshi, 78, 348–356 (2022) (in Japanese). – reference: 11) JC. DICKSON, IS. ARMSTRONG, PM. GABIÑA, AM. DENIS-BACELAR, AK KRIZSAN, et al.; EANM practice guideline for quantitative SPECT-CT, Eur. J. Nucl. Med. Mol. Imaging, 50 (4), 980–995 (2023). – reference: 31) L. JØDAL; Beta emitters and radiation protection, Acta. Oncol., 48, 308–313 (2009). – reference: 36) T. MURATA, K. MIWA, F. MATSUBAYASHI, K. WAGATSUMA, K. AKIMOTO, et al.; Optimal radiation shielding for beta and bremsstrahlung radiation emitted by(89)Sr and (90)Y: validation by empirical approach and Monte Carlo simulations, Ann. Nucl. Med., 28, 617–622 (2014). |
| SSID | ssib000936115 ssj0000400188 ssib004296017 ssib023161135 ssib002223929 ssib053390712 |
| Score | 2.356033 |
| SourceID | jstage |
| SourceType | Publisher |
| StartPage | 73 |
| SubjectTerms | alpha-ray beta-ray dosimetry nuclear medicine radio-theranostics targeted radionuclide therapy |
| Subtitle | これからの発展に向けた課題と取り組み |
| Title | 核医学治療の医療利用（2） |
| URI | https://www.jstage.jst.go.jp/article/jhps/59/2/59_73/_article/-char/ja |
| Volume | 59 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | 保健物理, 2024/06/06, Vol.59(2), pp.73-82 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV07b9RAELZCaGgQCBBvpWBKH2fvw7vl-uJTBAIJKZHSWXe2T3BFiOBo6EIVJEoaOioEBRRUSMm_QZeU-Qt8sz77jBSJEOlkrcezM7M7dzffrHbHQfCgkhxlRBSK0bgMpazKkGtAh2VfTJBPSFP5wvNPnuqNLfloW22vXNjrni6ZjXvF21PPlZzHq6DBr3xK9j882woFAW34F1d4GNcz-ZgyTa5PqaFMkRlQmnLDrZPT_CiNPSUha8nElAnARnJZh7l9BIohZz1FkoPAIaUDEOOmZbswljJJ6ZDsuu8JoYp7GtuI6JNpV_y8SVmjd8jWwq3-RnnTNVlDJuvyM5ugzHglUc0PsSml0quG0emSH2oFuaGfDcGKPL8l62AGi2MpyZIf2hylkX8Sk4sae9ATiplqob67HhJLv29Lt99gb4XhbSIsDVM3YAMdiH6YsBSWsAsEWeWZHX94rImfLTQGvte_J7LjU8musK7z7y00n79c7Nmt6uhijAwTVb9AoQk_i4LoLzqrAHUsqV_x0qCS-LR4B_jLdTemz3df95TtNT3-qh---HbmzJQrm8d8SUTe0Pl0Xz5FinExThK_0-Hxsw5CtwKD6CBqwMkuogacQUrfIlhkC2BfInAkExYgNm6XPTlmRP5tsO0E1UWDeSgPlwMBIJwiPWq2Vnq0t3kluLxI09Zcbf3VYGU6uhbQ0edf8w8H8-9fjn4eHH9693vvB27RmO9_O_749eRwPz45fH892Bpmm4ONcPGakXCKQD8KywlnTRaZiVFWlhpBrwRINkkpqrHSQsRjXRpjlZCF0YnAqCTXhCoKZS3yC3EjWN15uVPdDNaqYqKR4BRRMSmlLspREZW6nBQCec2kEvJWoOtR5bt1LZn8jN65fd6Od4JLyx_J3WB19upNdQ8weja-7x39B0GLlmU |
| linkProvider | Colorado Alliance of Research Libraries |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E6%A0%B8%E5%8C%BB%E5%AD%A6%E6%B2%BB%E7%99%82%E3%81%AE%E5%8C%BB%E7%99%82%E5%88%A9%E7%94%A8%EF%BC%882%EF%BC%89&rft.jtitle=%E4%BF%9D%E5%81%A5%E7%89%A9%E7%90%86&rft.au=%E5%AE%AE%E5%8F%B8%2C+%E5%85%B8%E6%98%8E&rft.au=%E5%8F%B3%E8%BF%91%2C+%E7%9B%B4%E4%B9%8B&rft.au=%E9%A3%AF%E6%A3%AE%2C+%E9%9A%86%E5%BF%97&rft.au=%E8%8A%B1%E5%B2%A1%2C+%E5%AE%8F%E5%B9%B3&rft.date=2024-06-06&rft.pub=%E4%B8%80%E8%88%AC%E7%A4%BE%E5%9B%A3%E6%B3%95%E4%BA%BA%E6%97%A5%E6%9C%AC%E4%BF%9D%E5%81%A5%E7%89%A9%E7%90%86%E5%AD%A6%E4%BC%9A&rft.issn=0367-6110&rft.eissn=1884-7560&rft.volume=59&rft.issue=2&rft.spage=73&rft.epage=82&rft_id=info:doi/10.5453%2Fjhps.59.73&rft.externalDocID=article_jhps_59_2_59_73_article_char_ja |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0367-6110&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0367-6110&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0367-6110&client=summon |